---
title: Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy
  in pediatric patients with relapsed/refractory leukemia
date: '2024-04-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38658354/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240425181103&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor (CAR) T cell therapy is a promising treatment
  for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia
  (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T cell
  therapy and fever is often the first symptom. Differentiating CRS from infection
  after CAR T cell therapy can be challenging. Plasma microbial cell free DNA (mcfDNA)
  is a novel diagnostic tool which allows for qualitative and quantitative assessment
  of ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T cell therapy and fever is often the first symptom. Differentiating CRS from infection after CAR T cell therapy can be challenging. Plasma microbial cell free DNA (mcfDNA) is a novel diagnostic tool which allows for qualitative and quantitative assessment of ...